심부전 POC 및 LOC 기기 시장 분석 보고서 : 유형별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Heart Failure POC And LOC Devices Market Growth & Trends:

The global heart failure POC and LOC devices market size is expected to reach USD 251.02 million by 2030 and is projected to grow at a CAGR of 15.09% from 2025 to 2030, according to a new report by Grand View Research, Inc. A paradigm shift in diagnostic sectors from late-stage disease detection to early identification of diseases as a viable strategy to curb rising healthcare costs has driven the market. This shift has led to the development of disposable and low-cost LOC devices that integrate various sensors and associated accessories in a single space for detection of the cardiac biomarkers from a single specimen to evaluate the risk of having a heart attack.

Furthermore, the development of predictive modeling techniques-based decision support software to analyze the data measured by the LOC assays to enable therapy monitoring is one of the key market drivers. Also, ongoing studies on the application of saliva-based nano-biochip tests for measuring myocardial infarction is driving organic revenue growth.

POC testing exhibits potential savings across various settings, including hospitals, general practice, and remote areas. In the U.S., the employment of POC devices resulted in a 20% decrease in hospital admissions to the chest pain unit, resulting in substantial savings in time and costs.

In the cardiac observation unit (U.S.), the implementation of POC troponin testing helped reduce hospital stays, decrease admission rates, and remove the need for multiple costly procedures, resulting in 25% cost saving per patient. Furthermore, the integration of smartphones and apps in POC diagnostics for managing the cardiac health of an individual is one of the significant innovations in Heart Failure POC & LOC Devices market.

Heart Failure POC And LOC Devices Market Report Highlights:

• Proteomic analysis includes products that test protein markers, such as troponin, myoglobin, and Creatine Kinase MB Isoenzyme (CK-MB)
• This segment accounted for the leading revenue share, as most of the currently available products are based on testing of protein markers
• Increasing implementation of microfluidic LOC technology for assessing putative biomarkers has led to the largest revenue share of this technology
• Microfluidic technology has been implemented for various biological applications, such as immunohybridization techniques, enzymatic assays, PCR, and others
• Clinics that include physician's office, pharmacy & retail clinics, urgent care clinics, and non-practice clinics are the key revenue generating end-users
• A high usage rate of POC devices by general practitioners for rapid investigation, deciding early treatment, timely referral, and less uncertainty for patients has driven the revenue growth through clinics
• The U.S. dominated the global Heart Failure POC & LOC devices market owing to the presence of a substantial number of primary care clinics that are deploying POC cardiac marker test as a measure for early detection of heart failure
• Expanding urbanization and increasing geriatric population underpin the demand for robust and improved healthcare services such as POC diagnostics for routine cardiac health monitoring in Asian countries
• Moreover, initiatives are undertaken for training young healthcare personnel about POC cardiac troponin T/cardiac troponin I biomarkers. This, in turn, is anticipated to result in the surging adoption rate of POC devices in Asian countries

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Information Procurement
• 1.2. Information or Data Analysis
• 1.3. Market Scope & Segment Definition
• 1.4. Market Model
  • 1.4.1. Market Study, By Company Market Share
  • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
• 3.5. Market Restraint Analysis
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Type Business Analysis

• 4.1. Heart Failure POC & LOC Devices Market: Type Movement Analysis
• 4.2. Proteomic Testing
  • 4.2.1. Proteomic Testing Market, 2018 - 2030 (USD Million)
• 4.3. Metabolomic Testing
  • 4.3.1. Metabolomic Testing Market, 2018 - 2030 (USD Million)
• 4.4. Genomic Testing
  • 4.4.1. Genomic Testing Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Heart Failure POC & LOC Devices Market: Technology Movement Analysis
• 5.2. Microfluidics
  • 5.2.1. Microfluidics Market, 2018 - 2030 (USD Million)
• 5.3. Array-based Systems
  • 5.3.1. Array-based Systems Market, 2018 - 2030 (USD Million)
• 5.4. Others
  • 5.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

• 6.1. Heart Failure POC & LOC Devices Market: End-use Movement Analysis
• 6.2. Hospitals
  • 6.2.1. Hospitals Market, 2018 - 2030 (USD Million)
• 6.3. Laboratories
  • 6.3.1. Laboratories Market, 2018 - 2030 (USD Million)
• 6.4. Clinics
  • 6.4.1. Clinics Market, 2018 - 2030 (USD Million)
• 6.5. Home
  • 6.5.1. Home Market, 2018 - 2030 (USD Million)
• 6.6. Assisted Living Healthcare Facilities
  • 6.6.1. Assisted Living Healthcare Facilities Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Heart Failure POC & LOC Devices Market Share By Region, 2024 & 2030
• 7.2. North America
  • 7.2.1. North America Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Target Disease Prevalence
    • 7.2.2.3. Competitive Scenario
    • 7.2.2.4. Regulatory Framework
    • 7.2.2.5. Reimbursement Scenario
    • 7.2.2.6. U.S. Heart failure POC & LOC devices Market, 2018 - 2030 (USD MILLION)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. Reimbursement Scenario
    • 7.2.3.6. Canada Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Target Disease Prevalence
    • 7.2.4.3. Competitive Scenario
    • 7.2.4.4. Regulatory Framework
    • 7.2.4.5. Reimbursement Scenario
    • 7.2.4.6. Mexico Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.3.2. Germany
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. Regulatory Framework
    • 7.3.2.5. Reimbursement Scenario
    • 7.3.2.6. Germany Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.3.3. UK
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Reimbursement Scenario
    • 7.3.3.6. UK Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Reimbursement Scenario
    • 7.3.4.6. France Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. Reimbursement Scenario
    • 7.3.5.6. Italy Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Reimbursement Scenario
    • 7.3.6.6. Spain Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Reimbursement Scenario
    • 7.3.7.6. Denmark Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Reimbursement Scenario
    • 7.3.8.6. Sweden Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Reimbursement Scenario
    • 7.3.9.6. Norway Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Regulatory Framework
    • 7.4.2.5. Reimbursement Scenario
    • 7.4.2.6. Japan Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Reimbursement Scenario
    • 7.4.3.6. China Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. Reimbursement Scenario
    • 7.4.4.6. India Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. Reimbursement Scenario
    • 7.4.5.6. South Korea Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Reimbursement Scenario
    • 7.4.6.6. Australia Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Reimbursement Scenario
    • 7.4.7.6. Thailand Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. Regulatory Framework
    • 7.5.2.5. Reimbursement Scenario
    • 7.5.2.6. Brazil Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Reimbursement Scenario
    • 7.5.3.6. Argentina Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Regulatory Framework
    • 7.6.2.5. Reimbursement Scenario
    • 7.6.2.6. South Africa Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. Reimbursement Scenario
    • 7.6.3.6. Saudi Arabia Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Reimbursement Scenario
    • 7.6.4.6. UAE Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. Reimbursement Scenario
    • 7.6.5.6. Kuwait Heart failure POC & LOC devices Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Abbott
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.1.3. Collection Site Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Danahar
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.2.3. Collection Site Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Siemens Healthineers
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.3.3. Collection Site Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. F. Hoffmann-La Roche Ltd.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.4.3. Collection Site Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Quidel Corporation
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.5.3. Collection Site Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. bioMerieux S.A
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.6.3. Collection Site Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Trinity Biotech
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.7.3. Collection Site Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Abaxis, Inc
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.8.3. Collection Site Benchmarking
    • 8.4.8.4. Strategic Initiatives